EU Approves Liso-Cel in R/R MCL With ≥ 2 Prior Lines of Systemic Therapy
As we march forward in the battle against cancer, significant strides have been made. From refined management techniques of Immune-Checkpoint Inhibitor toxicities in Melanoma to achieved milestones with novel drug mechanisms, the advances are promising.
Refining Management of Immune-Checkpoint Inhibitor Toxicities in Melanoma: Strategies to combat toxicities associated with Immune-Checkpoint Inhibitors in Melanoma are being refined to improve patient outcomes and ensure holistic care.
FDA Grants Fast Track Designation to SRN-101 for Recurrent High-Grade Glioma: The SRN-101 medicine has received fast-track designation from the FDA, marking an important stride forward in the treatment of recurrent high-grade glioma.
Novel Small Molecule Shows Early Activity in Pretreated Multiple Myeloma: A novel small molecule shows promise in treating multiple myeloma, putting forth a fresh avenue to explore in continued research.
Comparing Quality of Life Outcomes with Protons vs Photons in OPSCC: Comparisons between proton and photon therapies reveal differential outcomes in quality of life for OPSCC patients.
3 Things You Should Know About PSMA-Directed Imaging and Radioligand Therapy in Prostate Cancer: PSMA-Directed Imaging and Radioligand Therapy in Prostate Cancer is under active investigation, advancing our understanding and management of the disease.
